Association between methylation of tumor suppressor gene SOCS1 and acute myeloid leukemia

Zhang,Xiao‑Hui; Yang,Lin; Liu,Xiao‑Jun; Zhan,Ying; Pan,Yu‑Xia; Wang,Xing‑Zhe; Luo,Jian‑Min

doi:10.3892/or.2018.6508

Association between methylation of tumor suppressor gene SOCS1 and acute myeloid leukemia

Authors:
- Xiao‑Hui Zhang
- Lin Yang
- Xiao‑Jun Liu
- Ying Zhan
- Yu‑Xia Pan
- Xing‑Zhe Wang
- Jian‑Min Luo
View Affiliations

Affiliations: Department of Hematology, The Second Hospital of Hebei Medical University, Key Laboratory of Hematology, Shijiazhuang, Hebei 050000, P.R. China
Published online on: June 19, 2018 https://doi.org/10.3892/or.2018.6508
Pages: 1008-1016

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Suppressor of cytokine signaling‑1 (SOCS1) is a widely recognized tumor suppressor gene. Silencing of SOCS1 expression as a result of promoter methylation is associated with occurrence and development of solid tumors such as liver, cervical and pancreatic cancer. However, the association between SOCS1 gene methylation and acute myeloid leukemia (AML) has not been well explored. In the present study, we examined whether gene expression and methylation status of SOCS1 was altered in AML, and whether this was related to disease occurrence and development. To assess this hypothesis, we analyzed SOCS1 in four groups of AML patients: i) Initial treatment group (IT); ii) relapsed/refractory group (RR); iii) remission group (RE); and iv) normal control group (NC). We also used leukemia cell lines U937 and THP‑1 to study the underlying molecular mechanism of SOCS1 in AML, mainly the JAK2/STAT pathway. We used several techniques such as quantitative PCR (qPCR), methylation‑specific PCR (MS‑PCR), western blotting, flow cytometry and cell transfection techniques to analyze the expression and methylation status of SOCS1. We found that the SOCS1 gene methylation rate in the IT and RR groups was significantly higher than that in the RR and NC groups (48, 80 vs. 0 and 0%, respectively). Furthermore, mRNA and protein expression was significantly lower in the IT and RR groups when compared to the RE and NC groups. We also found that the JAK2/STAT signaling pathway was negatively affected by SOCS1. SOCS1 gene methylation caused gene silencing of SOCS1 which overcame the suppression of the downstream JAK2/STAT signaling pathway by SOCS1, and promoted the growth and proliferation of AML cells.

View Figures

View References

1	Walter RB, Othus M, Burnett AK, Löwenberg B, Kantarjian HM, Ossenkoppele GJ, Hills RK, Ravandi F, Pabst T, Evans A, et al: Resistance prediction in AML: Analysis of 4601 patients from MRC/NCRI, HOVON/SAKK, SWOG and MD Anderson Cancer Center. Leukemia. 29:312–320. 2015. View Article : Google Scholar : PubMed/NCBI
2	Ramos NR, Mo CC, Karp JE and Hourigan CS: Current approaches in the treatment of relapsed and refractory acute myeloid leukemia. J Clin Med. 4:665–695. 2015. View Article : Google Scholar : PubMed/NCBI
3	Zhang J, Li H, Yu JP, Wang SE and Ren XB: Role of SOCS1 in tumor progression and therapeutic application. Int J Cancer. 130:1971–1980. 2012. View Article : Google Scholar : PubMed/NCBI
4	Trengove MC and Ward AC: SOCS proteins in development and disease. Am J Clin Exp Immunol. 2:1–29. 2013.PubMed/NCBI
5	Skjesol A, Liebe T, Iliev DB, Thomassen EI, Tollersrud LG, Sobhkhez M, Lindenskov Joensen L, Secombes CJ and Jørgensen JB: Functional conservation of suppressors of cytokine signaling proteins between teleosts and mammals: Atlantic salmon SOCS1 binds to JAK/STAT family members and suppresses type I and II IFN signaling. Dev Comp Immunol. 45:177–189. 2014. View Article : Google Scholar : PubMed/NCBI
6	Lesinski GB, Zimmerer JM, Kreiner M, Trefry J, Bill MA, Young GS, Becknell B and Carson WE III: Modulation of SOCS protein expression influences the interferon responsiveness of human melanoma cells. BMC Cancer. 10:1422010. View Article : Google Scholar : PubMed/NCBI
7	Beaurivage C, Champagne A, Tobelaim WS, Pomerleau V, Menendez A and Saucier C: SOCS1 in cancer: An oncogene and a tumor suppressor. Cytokine. 82:87–94. 2016. View Article : Google Scholar : PubMed/NCBI
8	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2^−ΔΔCT method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
9	Chen CY, Tsay W, Tang JL, Shen HL, Lin SW, Huang SY, Yao M, Chen YC, Shen MC, Wang CH and Tien HF: SOCS1 methylation in patients with newly diagnosed acute myeloid leukemia. Genes Chromosomes Cancer. 37:300–305. 2003. View Article : Google Scholar : PubMed/NCBI
10	Chu PY, Yeh CM, Hsu NC, Chang YS, Chang JG and Yeh KT: Epigenetic alteration of the SOCS1 gene in hepatocellular carcinoma. Swiss Med Wkly. 140:w130652010.PubMed/NCBI
11	Sobti RC, Singh N, Hussain S, Suri V, Nijhawan R, Bharti AC, Bharadwaj M and Das BC: Aberrant promoter methylation and loss of suppressor of cytokine signalling-1 gene expression in the development of uterine cervical carcinogenesis. Cell Oncol. 34:533–543. 2011. View Article : Google Scholar
12	Hussain S, Singh N, Salam I, Bandil K, Yuvaraj M, Akbar Bhat M, Muzaffar Mir M, Siddiqi MA, Sobti RC, Bharadwaj M, et al: Methylation-mediated gene silencing of suppressor of cytokine signaling-1 (SOCS-1) gene in esophageal squamous cell carcinoma patients of Kashmir valley. J Recept Signal Transduct Res. 31:147–156. 2011. View Article : Google Scholar : PubMed/NCBI
13	Sakamoto LH, DE Camargo B, Cajaiba M, Soares FA and Vettore AL: MT1G hypermethylation: A potential prognostic marker for hepatoblastoma. Pediatr Res. 67:387–393. 2010. View Article : Google Scholar : PubMed/NCBI
14	Jiang S, Zhang HW, Lu MH, He XH, Li Y, Gu H, Liu MF and Wang ED: MicroRNA-155 functions as an OncomiR in breast cancer by targeting the suppressor of cytokine signaling 1 gene. Cancer Res. 70:3119–3127. 2010. View Article : Google Scholar : PubMed/NCBI
15	Babar IA, Cheng CJ, Booth CJ, Liang X, Weidhaas JB, Saltzman WM and Slack FJ: Nanoparticle-based therapy in an in vivo microRNA-155 (miR-155)-dependent mouse model of lymphoma. Proc Natl Acad Sci USA. 109:E1695–E1704. 2012. View Article : Google Scholar : PubMed/NCBI
16	Kobayashi N, Uemura H, Nagahama K, Okudela K, Furuya M, Ino Y, Ito Y, Hirano H, Inayama Y, Aoki I, et al: Identification of miR-30d as a novel prognostic maker of prostate cancer. Oncotarget. 3:1455–1471. 2012. View Article : Google Scholar : PubMed/NCBI
17	Park Y, Shon SK, Kim A, Kim KI, Yang Y, Cho DH, Lee MS and Lim JS: SOCS1 induced by NDRG2 expression negatively regulates STAT3 activation in breast cancer cells. Biochem Biophys Res Commun. 363:361–367. 2007. View Article : Google Scholar : PubMed/NCBI
18	Iwahori K, Serada S, Fujimoto M, Ripley B, Nomura S, Mizuguchi H, Shimada K, Takahashi T, Kawase I, Kishimoto T and Naka T: SOCS-1 gene delivery cooperates with cisplatin plus pemetrexed to exhibit preclinical antitumor activity against malignant pleural mesothelioma. Int J Cancer. 132:459–471. 2013. View Article : Google Scholar : PubMed/NCBI
19	Doti N, Scognamiglio PL, Madonna S, Scarponi C, Ruvo M, Perretta G, Albanesi C and Marasco D: New mimetic peptides of the kinase-inhibitory region (KIR) of SOCS1 through focused peptide libraries. Biochem J. 443:231–240. 2012. View Article : Google Scholar : PubMed/NCBI
20	Xiong H, Du W, Zhang YJ, Hong J, Su WY, Tang JT, Wang YC, Lu R and Fang JY: Trichostatin A, a histone deacetylase inhibitor, suppresses JAK2/STAT3 signaling via inducing the promoter-associated histone acetylation of SOCS1 and SOCS3 in human colorectal cancer cells. Mol Carcinog. 51:174–184. 2012. View Article : Google Scholar : PubMed/NCBI